Department of Radiology, Gate Tower Institute for Image Guided Therapy, 11F, Gate Tower Building, 1-Rinku Ohrai-Kita, Izumisano, Osaka, 598-0048, Japan.
Int J Clin Oncol. 2011 Oct;16(5):613-6. doi: 10.1007/s10147-010-0181-3. Epub 2011 Jan 21.
This is the first case report describing transcatheter arterial chemoembolization (TACE) with docetaxel-loaded microspheres which was successful in controlling liver metastases. We report on a 50-year-old woman with unresectable liver metastases from colorectal cancer. Since November 2007, the patient had received 12 courses of mFOLFOX6 (LV/5-FU/L-OHP) as the 1st line therapy, 18 courses of LV/5-FU as the 2nd line therapy, 16 courses of FOLFIRI (LV/5-FU/CPT-11) + bevacizumab as the 3rd line therapy, and 32 courses of cetuximab as the 4th line therapy. All treatments had been conducted after confirmation of the disease progression. The patient experienced hepatic dysfunction, upper abdominal pain and malaise due to the growth of metastatic liver tumors. Since December 2009, the patient received 3 courses of TACE with docetaxel-loaded microspheres in combination with hepatic arterial infusion of 20 mg cisplatin (CDDP) in a palliative setting for the treatment of liver metastases, which resulted in a reduction or necrosis of liver metastases and improvement in hepatic function and symptoms. TACE with docetaxel-loaded microspheres may be a palliative therapy for patients with colorectal cancer who are refractory to the current standard systemic chemotherapy and have predominant liver metastases.
这是首例描述经导管动脉化疗栓塞术(TACE)联合载多西紫杉醇微球治疗肝转移的病例报告。我们报告了一位 50 岁的女性,她患有结直肠癌无法切除的肝转移。自 2007 年 11 月以来,该患者已接受了 12 个疗程的 mFOLFOX6(LV/5-FU/L-OHP)一线治疗,18 个疗程的 LV/5-FU 二线治疗,16 个疗程的 FOLFIRI(LV/5-FU/CPT-11)+贝伐单抗三线治疗,以及 32 个疗程的西妥昔单抗四线治疗。所有治疗均在疾病进展后进行。由于转移性肝肿瘤的生长,患者出现肝功能障碍、上腹痛和不适。自 2009 年 12 月以来,该患者在姑息治疗的情况下接受了 3 个疗程的 TACE 联合载多西紫杉醇微球与肝动脉内灌注 20mg 顺铂(CDDP)治疗肝转移,结果肝转移瘤缩小或坏死,肝功能和症状改善。载多西紫杉醇微球的 TACE 可能是对当前标准全身化疗耐药且主要有肝转移的结直肠癌患者的一种姑息性治疗。